Graham Capital Management L.P. Makes New Investment in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Graham Capital Management L.P. acquired a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 5,490 shares of the medical instruments supplier’s stock, valued at approximately $506,000.

Several other hedge funds and other institutional investors have also made changes to their positions in LMAT. Smartleaf Asset Management LLC lifted its stake in LeMaitre Vascular by 234.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier’s stock valued at $39,000 after acquiring an additional 293 shares during the last quarter. CBIZ Investment Advisory Services LLC raised its holdings in shares of LeMaitre Vascular by 38.5% in the 4th quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier’s stock valued at $39,000 after purchasing an additional 117 shares during the period. KBC Group NV lifted its stake in LeMaitre Vascular by 58.4% in the 4th quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier’s stock valued at $102,000 after purchasing an additional 410 shares during the last quarter. Huntington National Bank grew its holdings in LeMaitre Vascular by 64.9% during the fourth quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier’s stock worth $107,000 after purchasing an additional 455 shares during the period. Finally, Empowered Funds LLC acquired a new position in LeMaitre Vascular during the fourth quarter worth approximately $150,000. 84.64% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Oppenheimer cut LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Lake Street Capital lifted their price objective on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Wells Fargo & Company started coverage on shares of LeMaitre Vascular in a research note on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 price target on the stock. Finally, Barrington Research downgraded shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Five investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $98.14.

LeMaitre Vascular Trading Up 0.4%

NASDAQ LMAT opened at $83.30 on Friday. The company has a market cap of $1.88 billion, a P/E ratio of 45.52, a PEG ratio of 2.22 and a beta of 0.86. The company has a fifty day simple moving average of $84.14 and a 200 day simple moving average of $92.95. LeMaitre Vascular, Inc. has a 12-month low of $71.42 and a 12-month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.02). The business had revenue of $59.87 million during the quarter, compared to analyst estimates of $57.61 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company’s revenue was up 12.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.44 EPS. Sell-side analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, May 29th. Shareholders of record on Thursday, May 15th will be given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.96%. The ex-dividend date is Thursday, May 15th. LeMaitre Vascular’s dividend payout ratio is currently 40.40%.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of the company’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the sale, the insider now directly owns 5,564 shares of the company’s stock, valued at $456,915.68. This represents a 26.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 10.79% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.